In a nutshell This study investigated the effectiveness and safety of capecitabine (Xeloda) as maintenance therapy versus active monitoring for the treatment of patients with stable metastatic colorectal cancer (mCRC). The data showed that capecitabine maintenance improved survival without cancer worsening with manageable side effects for these...
Read MoreCurrent treatment status-Undergoing active treatment-Partial response Posts on Medivizor
Evaluating CAR-T cell therapies for treating blood cancers
In a nutshell This study aimed to review the safety and effectiveness of three chimeric antigen receptor (CAR) T cell therapies, axicabtagene ciloleucel (AXI; Yescarta), tisagenlecleucel (TIS; Kymriah), and lisocabtagene maraleucel (LIS; Breyanzi), for the treatment of blood cancers. This...
Read MoreEvaluating long-term outcomes of autologous SCT for patients with recurrent multiple myeloma
In a nutshell This study evaluated the outcomes of autologous stem cell transplantation (ASCT) for patients with recurrent multiple myeloma (MM). This study found that long-term outcomes for these patients were promising, especially for patients who had the transplant right away after a first relapse. Some background Multiple myeloma (MM) is a type of...
Read MoreAdding daratumumab to pomalidomide and dexamethasone therapy for treatment of relapsed/refractory multiple myeloma.
In a nutshell This study evaluated the effectiveness and safety of adding daratumumab (Darzalex) to pomalidomide (Pomalyst) and dexamethasone (Decadron) therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that adding daratumumab to pomalidomide and dexamethasone regimen reduced the risk of...
Read MoreEvaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL
In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...
Read MoreEvaluating CAR T-cell therapy before stem cell transplantation for patients with B-cell ALL
In a nutshell This study evaluated the safety and effectiveness of CAR T-cell therapy versus chemotherapy before a stem cell transplant (SCT) for patients with recurrent or non-responsive B-cell acute lymphoblastic lymphoma (B-ALL). The authors concluded that CAR T-cell therapy followed by SCT was safe and effective for these patients. Some background...
Read MoreHow effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?
In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL). The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...
Read MoreHow effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?
In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...
Read MoreNivolumab improves survival in patients with non-small cell lung cancer in the long-term.
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...
Read MoreImproved outcomes for relapsed/refractory multiple myeloma patients treated with daratumumab.
In a nutshell This study evaluated the effect of daratumumab (Darzalex)-based treatments on sustained minimal residual disease (MRD) negativity and outcomes in patients with relapsed/refractory (RR) multiple myeloma (MM). The data showed that treatments including daratumumab led to sustained MRD negativity and improved outcomes in these...
Read MoreBlinatumomab or inotuzumab ozogamicin as a bridge to stem cell transplant in relapsed/refractory B-cell acute lymphoblastic leukemia
In a nutshell This study aimed to evaluate the use of blinatumomab Blincyto; B) or inotuzumab ozogamicin (Besponsa; IO) as a bridge to stem cell transplant for patients with relapsed or refractory (unresponsive) B-cell acute lymphocytic leukemia (B-ALL). This study concluded that both treatments are safe and effective as a...
Read MoreComparing salvage treatments for relapsed/refractory acute myeloid leukemia
In a nutshell This study aimed to compare outcomes of salvage chemotherapy for patients with relapsed or refractory acute myeloid leukemia. This study concluded that the CLAG-M regimen (cladribine, cytarabine, filgrastim, and mitoxantrone) followed by transplant is a suitable salvage treatment for these patients. Some...
Read More